Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Details

Language :

English

ISSN :

25233548

Volume :

41

Issue :

9

Database :

Complementary Index

Journal :

Cancer Communications

Publication Type :

Academic Journal

Accession number :

152469485

Full Text :

https://doi.org/10.1002/cac2.12179